| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.01 | 0.8 |